AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. (ABBV) EPS (diluted)
AbbVie Inc.'s EPS (diluted) for fiscal 2025 was $2.36, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $3.54. Over the past ten years it has ranged from $2.36 (fiscal 2025) to $6.63 (fiscal 2022) — the current reading is the lowest in ten years. EPS (diluted) has fallen for 3 consecutive fiscal years. AbbVie Inc. ranks 9th of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.36 | (1.26%) |
| FY2024 | $2.39 | (12.13%) |
| FY2023 | $2.72 | (58.97%) |
| FY2022 | $6.63 | 2.79% |
| FY2021 | $6.45 | 137.13% |
| FY2020 | $2.72 | (48.48%) |
| FY2019 | $5.28 | 44.26% |
| FY2018 | $3.66 | 10.91% |
| FY2017 | $3.30 | (9.09%) |
| FY2016 | $3.63 | 15.97% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $2.03 | 420.51% |
| Mar 2026 | $0.39 | (61.76%) |
| Dec 2025 | $1.02 | 920.00% |
| Sep 2025 | $0.10 | (80.77%) |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LLY Eli Lilly and Company compare | $29.80 |
| AMGN Amgen Inc. compare | $16.09 |
| JNJ Johnson & Johnson compare | $8.63 |
| AZN AstraZeneca PLC compare | $6.69 |
| NVS Novartis AG compare | $6.63 |
| ABBV AbbVie Inc. | $3.54 |
| MRK Merck & Co., Inc. compare | $1.25 |
| PFE Pfizer Inc. compare | $0.76 |
| GILD Gilead Sciences, Inc. compare | −$2.67 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ABBV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement